Evidence map›Paper›PMID 40687919›Full record

ArticleGynecologic oncology reports2025

Racial differences in endometrial cancer genomics and outcomes using UNCseq

Meredith A Newton, Jason D Merker, Weida Gong, Sushant Patil, Xianming Tan, David L Cocoran, Adam D Pfefferle, Michele C Hayward, Russell Broaddus, Hazel B Nichols and 4 more

Abstract read
In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Meredith A NewtonUniversity of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, United States.
Jason D MerkerUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Weida GongUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Sushant PatilUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Xianming TanUniversity of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, United States.
David L CocoranUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Adam D PfefferleUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Michele C HaywardUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Russell BroaddusUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Hazel B NicholsUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Andrew F OlshanUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Bernard WeissmanUniversity of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, United States.
Temitope O KekuUniversity of North Carolina at Chapel Hill, Department of Medicine, Center for Gastrointestinal Biology and Disease, United States.
Victoria Bae-JumpUniversity of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To use an institution-sponsored targeted sequencing effort to characterize the genomic differences in endometrioid and serous endometrial cancers (ECs) between Black and White patients and to investigate the impact on clinical outcomes. Methods: Tumor tissue from Black and White patients with serous or endometrioid ECs underwent DNA sequencing using the UNCseq Results: Tumor tissue from 200 endometrioid or serous ECs were included, with 169 tumors (84.5 %) from White and 31 (15.5 %) from Black patients. Black patients more frequently had serous ( Conclusions: Several potential molecular drivers of the racial disparity in EC were identified. Future studies are warranted to validate the clinical impact of these findings amongst a larger diverse study population and evaluate their potential as clinically actionable targets in treatment.

Identifiers

PMID40687919
PMCPMC12274730

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.